ovarian cancer

AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field
AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field
Fierce Pharma
AbbVie
M&A
antibody-drug conjugate
Immunogen
Elahere
ovarian cancer
Flag link:
FDA grants IND clearance for ovarian cancer trial of Oncoinvent
FDA grants IND clearance for ovarian cancer trial of Oncoinvent
Clinical Trials Arena
Oncoinvent
FDA
Radspherin
ovarian cancer
Flag link:
Mendus shows early comparability data for its universal cancer vaccine
Mendus shows early comparability data for its universal cancer vaccine
Clinical Trials Arena
Mendus
vididencel
AML
ovarian cancer
vaccines
Flag link:
Novocure’s tumor-treating electric fields fall short in ovarian cancer trial
Novocure’s tumor-treating electric fields fall short in ovarian cancer trial
Clinical Trials Arena
Novocure
ovarian cancer
tumor treating fields
Flag link:
Cyteir finally calls it quits after months of cost cutting
Cyteir finally calls it quits after months of cost cutting
Fierce Biotech
Cyteir Therapeutics
ovarian cancer
dissolution
Flag link:
AstraZeneca, Merck's Lynparza picks up new NICE recommendation
AstraZeneca, Merck's Lynparza picks up new NICE recommendation
Fierce Pharma
AstraZeneca
Merck
Lynparza
NICE
UK
ovarian cancer
fallopian tube cancer
Flag link:
ASCO 2023: Precigen reports positive early data for CAR-T therapy
ASCO 2023: Precigen reports positive early data for CAR-T therapy
BioSpace
ASCO 2023
Precigen
CAR-T
PRGN-3005
ovarian cancer
Flag link:
AstraZeneca study points to new uses for targeted cancer drug Enhertu
AstraZeneca study points to new uses for targeted cancer drug Enhertu
BioPharma Dive
ASCO 2023
AstraZeneca
Enhertu
uterine cancer
cervical cancer
ovarian cancer
bladder cancer
Flag link:
ASCO: AstraZeneca guns for wider ovarian cancer market with Imfinzi-Lynparza combo. Will the FDA buy the plan?
ASCO: AstraZeneca guns for wider ovarian cancer market with Imfinzi-Lynparza combo. Will the FDA buy the plan?
Fierce Pharma
ASCO 2023
AstraZeneca
Lynparza
Imfinzi
ovarian cancer
Flag link:
ImmunoGen’s drug Elahere offers hope for ovarian cancer patients
ImmunoGen’s drug Elahere offers hope for ovarian cancer patients
Clinical Trials Arena
Immunogen
Elahere
clinical trials
platinum-resistant ovarian cancer
ovarian cancer
Flag link:
ImmunoGen reports positive top-line data from ovarian cancer therapy trial
ImmunoGen reports positive top-line data from ovarian cancer therapy trial
Clinical Trials Arena
Immunogen
clinical trial
ovarian cancer
platinum-resistant ovarian cancer
Elahere
Flag link:
Trailing AstraZeneca and Merck, Junshi reports phase 3 ovarian cancer success for Lynparza rival
Trailing AstraZeneca and Merck, Junshi reports phase 3 ovarian cancer success for Lynparza rival
Fierce Biotech
Junshi Biosciences
PARP inhibitors
ovarian cancer
Merck
AstraZeneca
Lynparza
Flag link:
GSK told to pay higher royalties to AZ on Zejula sales
GSK told to pay higher royalties to AZ on Zejula sales
Pharmaphorum
GSK
AstraZeneca
ovarian cancer
Zejula
legal
UK
Flag link:
AstraZeneca's Lynparza-Imfinzi combo clears PhIII trial in ovarian cancer
AstraZeneca's Lynparza-Imfinzi combo clears PhIII trial in ovarian cancer
Endpoints
AstraZeneca
Lynparza
Imfinzi
ovarian cancer
clinical trials
Flag link:
Amid bankruptcy, Clovis reveals more regulatory troubles for Rubraca
Amid bankruptcy, Clovis reveals more regulatory troubles for Rubraca
Fierce Pharma
Clovis Oncology
Rubraca
ovarian cancer
bankruptcy
Flag link:
Cyteir lays off 70% of workforce after further narrowing cancer drug goals
Cyteir lays off 70% of workforce after further narrowing cancer drug goals
Fierce Biotech
Cyteir Therapeutics
layoffs
CYT-0851
ovarian cancer
Flag link:
Sutro shells out latest update on ovarian cancer treatment, plans for pivotal trial
Sutro shells out latest update on ovarian cancer treatment, plans for pivotal trial
Endpoints
Sutro BioPharma
clinical trials
antibody-drug conjugate
ovarian cancer
luveltamab tazevibulin
Flag link:
OncoC4 doses first participant in ovarian cancer therapy trial
OncoC4 doses first participant in ovarian cancer therapy trial
Clinical Trials Arena
OncoC4
clinical trials
ONC-392
Merck
Keytruda
ovarian cancer
platinum-resistant ovarian cancer
Flag link:
Compugen COM701 in dual/triple combo shows promise in ovarian cancer patients in trial
Compugen COM701 in dual/triple combo shows promise in ovarian cancer patients in trial
Seeking Alpha
CompuGen
COM701
Bristol Myers Squibb
Opdivo
ovarian cancer
platinum-resistant ovarian cancer
Flag link:
In free fall, Clovis defaults on loan and agrees to further restrict Rubraca use
In free fall, Clovis defaults on loan and agrees to further restrict Rubraca use
Fierce Pharma
Clovis Oncology
Rubraca
FDA
ovarian cancer
Flag link:

Pages